Feldmann 1992.

Methods	Method of randomisation not clear.
Participants	155 participants (median age 66 years; sex: see notes) with advanced small cell lung cancer treated with doxorubicin containing chemotherapy (cumulative dose nm; peak dose (i.e. maximal dose received in 1 week) 50 mg/m2; infusion duration nm). Prior anthracycline therapy nm. Prior cardiac radiotherapy nm. Prior cardiac dysfunction nm.
Interventions	Dexrazoxane (10:1 ratio of study drug to doxorubicin; within 30 minutes prior to doxorubicin by IV bolus) versus placebo (number of participants in each group nm).
Outcomes	Heart failure (defined as cardiac events): difference in favour of the dexrazoxane group. Other toxicities and tumour response rate: level of significance not mentioned.
Notes	Unclear if this is an ongoing or completed study. Length of follow‐up nm. Cumulative anthracycline dose per treatment group nm. Median age in both treatment groups 66 years. 70% of dexrazoxane participants were male and 62% of the control participants. 105 participants were evaluable: 43 in the intervention group and 62 in the control group.